At Pacific Biosciences of California, Inc. (NASDAQ:PACB), the ratio of insider selling to insider buying over a quarter is running at 1. Could this be a sign something is bothering insiders? PACB recorded 1 sales count on the open market in the last three months. They sold nearly 25,000 shares while purchases amounted to zero shares that period. Looking even further back to 12 months, corporate insiders offloaded 25,000 shares when buyers snapped up 152,500 shares. The 12-month’s totals signify about a 0.16-to-1 sell/buy ratio.
Ordonez Kathy parted with a total of 25 thousand shares of Pacific Biosciences of California, Inc. (PACB) at average share price of $7.54. This insider trade in the company took place on 11/27/2018. The total for the sales was set at $188.5 thousand. After this transaction, the Chief Commercial Officer account balance stood at 43.75 thousand shares. The stock grew 0.66 percent since that insider sale. On 10/28/2016, Phillips James Michael, SVP, Research & Development, sold 20 thousand shares at a price per share of $8.44. This removed 168.8 thousand shares from the insider’s fortune and the stock saw a -10.07 percent retreat in value since the news became public. This transaction left 181.45 thousand shares in the SVP, Research & Development account.
On 07/29/2016, SVP, Research & Development Phillips James Michael performed a sale transaction worth $169 thousand. This sale at $8.45 each has eliminated 20 thousand shares from the insider’s portfolio position. Meanwhile, shares have recorded -10.18 percent decrease since the transaction was reported. The insider now is left with 181.45 thousand shares remaining in the account. Phillips James Michael, who performs the SVP, Research & Development job, sold 20 thousand shares for $205.8 thousand. The disposal occurred on 04/25/2016 was priced at $10.29 per share. The share price plunged -26.24 percent since the reporting date. Phillips James Michael now left with a stake of 181.45 thousand PACB stock worth $1.4 million after the insider selling.
The 12-month median price target for Pacific Biosciences of California, Inc. (PACB) assigned by the analysts stands at $8, which represents a return potential of 3.9 percent when compared to the closing price of the stock of $7.7 on Thursday, December 06. The lowest price target for the stock is $6.5 — slightly more than -15.58 percent from PACB’s current share price. The stock will probably climb -16.62 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $8-month high price target. This represents a whopping 3.9 percent increase from where shares are trading today.
On momentum oscillators front, ‘RSI’ has touched 73.11 on daily chart, which may remain a cause for concern. If the price breaks below $7.47 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $7.76 mark may result into a pull-back move towards $7.81 level. The stock is currently hovering around the first support level of $7.59. Below this, the next support is placed in the zone of $7.47. Till the time, the PACB stock trades above this level, bulls have nothing to fear.
Shares of Pacific Biosciences of California, Inc. (PACB) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry PACB operates in has an average P/E of 52.98. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 13.27 on the Price-to-Sales ratio. Compare this with the industry average P/S of 11.09. 34.3 percent is the gross profit margin for Pacific Biosciences of California, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.
On 6th of December, Pacific Biosciences of California, Inc. (NASDAQ:PACB) shares ended higher after a volatile session. The shares accumulated 0.02 points or 0.26 percent at $7.7 with a heavy trade volume of 5.399 million shares. After opening the session at $7.65, the shares went as high as $7.7 and as low as $7.53, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $1.11 billion and now has 144.72 million shares outstanding. Pacific Biosciences of California, Inc. (PACB) stock has lost -0.65 percent of market value in 21 trading days.
In last reported earnings results, PACB earned -$0.19 per share, worse than the -$0.15, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $18.16M, worse than the $22.17M analysts expected. Earnings are estimated to increase by -4.6 percent this year, 29.9 percent next year and continue to increase by 30 percent annually for the next 5 years. Investors will get their next glimpse of PACB’s Q4 earnings on February 01. Analysts are forecasting revenue to suffer decline of -15.2 percent to $21.14M in the next fiscal quarter, while earnings are seen soaring by nearly -27.78 percent to -$0.13 per share. History has shown that shares in Pacific Biosciences of California, Inc. have gone down on 22 different earnings reaction days and are predicted to add 0.11 percent when the company reports upcoming earnings.
PACB stock has a trailing 3-year beta of 2.53, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.73 a share in the trailing twelve months. The stock’s value has surged 191.67 percent year to date (YTD) against a rise of 167.36 percent in 12 month’s time. The company’s shares still trade -1.79 percent away from its 1-year high of $7.84 and 281.19 percent up from 52-week low of $2.02. The average consensus rating on the company is 2.6, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a sell.